Unresectable Stage III or IV Melanoma
Unresectable Stage III or IV Melanoma is a serious skin cancer that cannot be surgically removed and has spread to nearby lymph nodes or other parts of the body.
Long-Term Safety of Miltenyi CAR T Cell Therapy
We are studying the long-term effects of Miltenyi CAR T cell therapy on patients, especially children. This includes monitoring safety, disease progression, and overall survival.
>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesInjectionDermatologyHematologyOncology
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma
Relapsed or refractory B Cell Non-Hodgkin's Lymphoma is a type of cancer that affects the lymphatic system and has either returned after treatment or has not responded to initial therapies.
Relapsed or Refractory CD20 Positive B-Cell Non-Hodgkin’s Lymphoma
This condition refers to a type of B-cell Non-Hodgkin's Lymphoma that expresses the CD20 protein and has either returned after treatment or has not responded to therapy.
Relapsed or Refractory CD19 Positive B Cell Malignancies (Pediatric)
This condition involves CD19 positive B cell malignancies in children, such as acute lymphoblastic leukemia (ALL), that have either returned or are resistant to treatment.
Relapsed or Refractory CD19 Positive B Cell Malignancies (Adult)
This condition refers to CD19 positive B cell malignancies in adults, including acute lymphoblastic leukemia and chronic lymphocytic leukemia, that have either recurred or are resistant to treatment.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Have you received Miltenyi CAR T cell therapy at least 12 months ago?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Mb-Cart19.1
Mb-Cart20.1
Mb-Cart2019.1
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Charite Universitaetsmedizin Berlin KöR
Pädiatrische Klinik Schwerpunkt Onkologie und Hämatologie
Berlin, Germany
Universitaetsklinikum Erlangen AöR
Medizinische Klinik 5
Erlangen, Germany
Universitaetsmedizin Goettingen
Klinik für Hämatologie und Medizinische Onkologie, Bereich Stammzelltransplantation
Göttingen, Germany
Sponsor: Miltenyi Biomedicine GmbH
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.